This company provides technology to medical researchers that lets them capture rare cells.
This one really is a bit of a secret. Signed up to plus for this and 4d Pharma. Check them out, liquid biopsy that detects live cancer cells from a blood test, potentially making personalised cancer treatments possible. Currently in talks with US FDA
1 Like
Seeing nice rise here. Still not too late for a long hold. Nice video at bottom of the link
1 Like
Thanks for the link, impressive stuff, I can see this doing very well long term, Up 29% in the last month !
How likely is the fda approval please? Does anyone know?
I guessing it’s already priced in but a short rise should be possible.
Doing well here on a down day
Just announced major contract and
still waiting for FDA approval hopefully H2 2021
Angle PLC Announces First Large-Scale Pharma Services Contract Secured
Published: Apr 16, 2021
- Contract Worth Up to US$1.2 Million With Potential for Further Contracts From the Same Customer
- Parsortix System Being Utilised in Cancer Drug Trials for Liquid Biopsy Longitudinal Monitoring Which Is Not Possible With Tissue Biopsies
GUILDFORD, UK / ACCESSWIRE / April 16, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that the Company has secured its first large-scale pharma services contract. The customer, a pharma company with numerous cancer drugs under development and revenues exceeding US$1 billion per annum, has selected ANGLE’s Parsortix® system to undertake longitudinal monitoring (i.e. before, during and after drug intervention) of patients in three separate global clinical trials in prostate cancer and other locally advanced and metastatic solid tumours.
The contract is expected to be worth up to US$1.2 million over some 18 months. The work relates to a large Phase III prostate cancer study and two smaller Phase I studies. The Phase I studies, if successful, could progress to larger Phase II studies and, if successful, much larger Phase III studies.
The services cover the capture, harvest and analysis of circulating tumor cells (CTCs) and CTC clusters. Samples are being shipped from multiple study centres to ANGLE’s clinical laboratories in the UK and United States for analysis using the Parsortix system.
The contract represents the first large-scale adoption of the Parsortix system for processing patient blood samples to help inform decision making in cancer drug trials. Importantly, the customer recognises the advantage in capturing mesenchymal as well as epithelial cancer cells and the importance that CTC clusters as well as single CTCs may have in the progression of disease, metastasis, and drug resistance.
The Parsortix liquid biopsy has particular advantages in capturing intact cancer cells including mesenchymal cells and clusters and provides the opportunity for longitudinal testing in a clinical setting, which is not possible with tissue biopsy. ANGLE believes that longitudinal monitoring of CTCs will prove highly attractive to the pharma industry looking for new insights in cancer drug trials.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
“We are delighted to have contracted with a pharma company developing numerous cancer drugs and look forward to working closely with them on their trials. ANGLE believes that there is a substantial business opportunity in providing services to pharma and biotech customers to support cancer drug trials. This contract demonstrates that our investment in clinical laboratories and a pharma services business, a key use of proceeds from our fundraising in October 2020, is already delivering. We look forward to announcing further progress on the expansion of this important business area for ANGLE in due course.”
https://webcast.openbriefing.com/angle-apr21/player/?player_id=42822
Excellent presentation from CEO for Prelim Results for YE 31/12/20
FDA SUBSTANTIVE REVIEW PROGRESSING
LAUNCH OF CLINICAL LABORATORY SERVICES
FIRST LARGE-SCALE CONTRACT WITH PHARMA CUSTOMER USING THE PARSORTIX SYSTEM IN CLINICAL TRIALS
PATIENT ENROLMENT COMPLETED IN OVARIAN CANCER CLINICAL VERIFICATION STUDY
overnight they raised £20m at a 7% discount
edit - my emphasis
Friday 25 June 2021
ANGLE plc
(“ANGLE” or the “Company”)
Result of Accelerated Bookbuild
Funds will allow the Company to pursue major prostate opportunity
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that, further to the announcement made yesterday, the Company has successfully raised gross proceeds of GBP20.0 million by conditionally placing 17,241,380 Placing Shares at a price of 116 pence per New Ordinary Share with new and existing investors.
The Issue Price represents a discount of approximately 6.83 per cent. to the closing mid-market price of an Ordinary Share of 124.50 pence on 23 June 2021. The Placing Shares represent approximately 7.40 per cent. of the Company’s Enlarged Issued Share Capital.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"We would like to thank our shareholders for their continued strong support and welcome new shareholders to the ANGLE register. The proceeds from this Placing will enable ANGLE to add to the current momentum in the commercialisation process of our Parsortix system and open up new market opportunities in Prostate Cancer diagnosis, an area of significant medical need. ANGLE looks forward to announcing further progress on multiple fronts in H2 CY21, including the prospect of FDA clearance for the Parsortix platform."
Use of Proceeds:
Prostate cancer opportunity GBP7m Building senior management team in the United States GBP3m ------- Assay development capability GBP2m ------- Ongoing operations for breast and ovarian cancers and strengthen balance sheet for pharma GBP8m services ------- Total GBP20m -------
RNS this am
Not the ‘FDA approval’ one we hope for
but still very interesting
yesterdays RNS reach was the third scientific study update in a week
I don’t have the requisite medical knowledge to understand it but I get the gist
ANGLE Founder and Chief Executive, Andrew Newland, said:
“The Advances in Circulating Tumour Cells (ACTC) conference is the pre-eminent event focused on exploring the promise of CTCs in cancer research and patient management. ANGLE is pleased to see further world-class research being presented by Prof. Zeillinger and his team, which has been enabled by the Parsortix system. These studies, including data from a large multicentre European clinical trial, build on the growing body of evidence supporting the use of the Parsortix system to provide cancer cells for analysis from a simple blood test and to uncover potentially valuable new cancer biomarkers, with the potential to guide drug development and inform treatment decisions.”
Mon, 27th Sep 2021 07:00
RNS Number : 9810M
Angle PLC
27 September 2021
For immediate release
27 September 2021
ANGLE plc (“the Company”)
Parsortix system demonstrates ability to isolate CTCs for downstream gene analysis revealing multiple prognostic biomarkers
Leading European study centre presents results of three studies in ovarian and lung cancer at 5th ACTC Conference
Novel CTC biomarkers found to predict progression free survival and treatment response for longitudinal patient monitoring in ovarian cancer
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the Molecular Oncology Group at the Medical University of Vienna, presented results of three studies at the 5th Advances in Circulating Tumour Cells (ACTC) conference, held 22-25 September in Kalamata, Greece.
The studies in ovarian cancer, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) patients, all utilised ANGLE’s biomarker-independent Parsortix® system to isolate circulating tumour cells (CTCs) from a simple blood draw.
The largest study, a Phase II drug trial including 133 ovarian cancer patients, explored longitudinal gene expression of CTCs isolated using the Parsortix system in platinum-resistant patients enrolled on the GANNET53 trial over a five year period with an average four time points for each patient. Gene expression analysis of genes expressed on CTCs isolated from successive blood draws correlated closely with significantly improved progression free survival and response to therapy. For example, at cycle 1, gene expression analysis of CTCs isolated by the Parsortix system could predict responders (with a survival rate of 85% at 120 days) compared to non-responders (with a survival rate of 30% at 120 days). This pattern was repeated at all the cycle points. In the conference poster, the researchers described this as a “landmark analysis”. This study demonstrates how gene expression analysis of CTCs, isolated by the Parsortix system, can be used in pharma drug trials for longitudinal patient monitoring and to guide treatment selection.
In the second study, researchers evaluated the detection of tumour protein p53 as a new marker for CTC detection in SCLC. p53 is coded for by the tumour suppressor gene TP53, which is mutated in 75-90% of SCLC patients and is the target of several novel drugs in clinical development. For the first time, the presence of p53 in CTCs was demonstrated, suggesting that they are a unique new marker for CTC detection. Furthermore, the presence of p53 aggregates is likely to be a valuable biomarker for targeted treatment selection, and of interest to pharma companies developing drugs targeting p53.
In the third study in NSCLC, the researchers performed qPCR molecular analysis on the CTCs captured by the Parsortix system in samples from 118 NSCLC patients and 30 healthy volunteers. The research demonstrated that the CTCs expressing EMT (epithelial mesenchymal transition) and/or cancer stem cell markers were the most clinically relevant for prognosis rather than CTCs expressing epithelial markers. This is significant because competing antibody-based CTC systems utilise epithelial markers for CTC capture and miss the CTCs that do not express these markers.
In addition, in matched samples, the gene expression analysed by qPCR of CTCs harvested by the Parsortix system was found to be more effective at prognostic analysis (predicting overall patient survival) than assessing the presence of epithelial CTCs.
These studies demonstrate that CTC analysis before and during treatment can provide non-invasive monitoring of cancer patients throughout their treatment pathway and that CTC gene expression profiles can determine progression free survival and response to therapy.
Ovarian cancer accounts for an estimated 21,400 cases in the United States in 2021 and is associated with poor patient outcomes. 57% of cases are diagnosed when the cancer has already metastasised and in these patients 5-year survival rates are just 30%. As such a clear need exists for biomarkers which can support personalised medicine and track patient response to optimise the care pathway.
Lung cancer is the second most common cause of cancer in the United States and the leading cause of cancer related mortality, responsible for 22% of all cancer related deaths. In 2021, The National Cancer Institute predicts that there will be a total of 236,000 new cases and 132,000 deaths - NSCLC accounts for 84% of all lung cancer cases. Whilst the overall 5-year survival rate for NSCLC is 25%, 60% of patients are diagnosed with metastatic (stage IV) disease for which the 5-year relative survival rate is just 5%. SCLC accounts for 13% of all lung cancer cases with a 5- year survival rate of just 7%.
RNS Number : 0200S
Angle PLC
11 November 2021
For immediate release
11 November 2021
ANGLE plc (“the Company”)
ANGLE’S PARSORTIX SYSTEM SHOWCASED IN POSTER PRESENTATION AT NATIONAL CANCER RESEARCH INSTITUTE (NCRI) FESTIVAL
Study in metastatic prostate cancer presented at NCRI Festival demonstrates longitudinal analysis of CTCs harvested using the Parsortix system is predictive of treatment response
KLK2 gene expression on CTCs found to be a more effective biomarker for assessing likelihood of cancer progression than current standard of care
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that a poster presentation showcasing the Parsortix® system was presented yesterday at the National Cancer Research Institute (NCRI) Festival, being held 8-12 November 2021. The poster showcases findings from a Barts Cancer Institute study in metastatic prostate cancer which undertook circulating tumour cell (CTC) analysis to evaluate docetaxel drug treatment response and resistance markers.
Longitudinal CTC sampling was performed using the Parsortix system in 56 patients. The samples were taken before patients started docetaxel treatment, during treatment, and after completing all doses over a period of 6-8 months. A total of 205 CTC samples were analysed for changes in CTC number, phenotype, and mRNA gene expression.
Multiplex qPCR analysis, using a custom designed 32 gene panel of CTC mRNA revealed that patients with disease progression who have worse predicted survival rates had high expression of the KLK2 gene at each blood collection time point and that this was significantly more predictive than the current standard of care for assessing the likelihood of progression, which is based on blood PSA levels. These findings are significant as they highlight KLK2 as a possible alternative and a better biomarker for prostate cancer prognosis.
This study concludes that longitudinal analysis of CTCs isolated using the Parsortix system can predict whether a patient is resistant or developing resistance to treatment with docetaxel. As such, it could be used as an early biomarker for treatment response. Study findings could enable doctors to detect early on, and without invasive procedures, if a treatment is working and switch to alternatives if it is not.
Prostate cancer is the leading cause of cancer in men and accounts for 13% of all new cancer cases in the United States. In 2021, the National Cancer Institute estimates that there will be 248,500 new cases in the United States with an additional 3.2 million men living with the disease. The current standard of care, transrectal ultrasound-guided prostate tissue biopsy, is an invasive procedure associated with clinical complications where 32% of patients will experience moderate side effects and 1.4% of patients experience major complications. This includes post-biopsy sepsis in 2-5% of cases with up to 25% requiring admission to ICU. Liquid biopsy offers the potential for safe, cost-effective longitudinal monitoring of tumour evolution and disease progression to track mutations responsible for therapy resistance and identify biomarkers for targeted treatment selection.
Caitlin Davies, study author and PhD research student at Barts Cancer Institute, Queen Mary University of London, UK, commented:
"This insight into how CTC dynamics lead to reduced progression-free and survival times is vital for clinicians. It will enable them to make early changes of treatment from docetaxel to an alternative, which may significantly improve patients’ chances of long-term survival. Furthermore, analysis of CTC gene expression and detection of genes associated with resistance to docetaxel may aid the development of a new generation of therapies.
Professor Hashim Ahmed, Chair of the NCRI Prostate Group and Professor of Urology at Imperial College London, UK, who was not involved in the research, said:
“These are promising results and have the potential to change clinical practice, if they are confirmed by further research. Assessing the responsiveness of an individual patient’s tumour to docetaxel treatment by means of blood tests will enable clinicians to personalise cancer treatment more easily and effectively, without the patient having to undergo invasive procedures such as tissue biopsies. It could also help to avoid patients undergoing unpleasant systemic treatments that are going to be unsuccessful.”
ANGLE Founder and Chief Executive, Andrew Newland, added:
“We are pleased that Barts has presented this promising data showcasing longitudinal analysis using the Parsortix system. Their findings not only demonstrated the Parsortix system’s potential to guide treatment decisions but also its ability to help identify new biomarkers for assessing likelihood of progression in prostate cancer and as possible targets for new drug therapy. This evidence provides further support for our pharma services business which offers longitudinal analysis for drug trials in multiple cancers and for our planned studies to develop a prostate cancer assay to offer as a laboratory developed test from our own laboratories.”
The poster and abstract are available at Publications/Posters - ANGLE PLC.
Still no news on FDA approval before end of year (probably unlikely, one must assume as only 1 week left)
scuttlebutt says that FDA is swamped due to the 'Rona
fingers x’d still
two more scientific papers published; 1 announced by RNS yesterday
ANGLE Founder and Chief Executive, Andrew Newland, commented:
“This study, which analysed blood samples taken from patients using the Parsortix system before and after treatment, further demonstrates the dynamic nature of NSCLC and the need for analysis of CTCs and not just ctDNA from serial liquid biopsies to provide information on disease progression and drug resistance. In addition to the clinical implications in guiding therapy decisions, this information is vital for drug companies in patient selection for clinical trials and for monitoring response to new drugs.”
EPIGENETIC ALTERATIONS IN GENES FROM LIQUID BIOPSIES PROVIDE INSIGHT INTO DRUG RESISTANCE IN NON-SMALL LUNG CANCER PATIENTS
Longitudinal analysis of paired samples of CTCs and ctDNA shows important differences in epigenetic biomarkers at disease progression
Study supports analysis of CTCs captured by Parsortix, together with ctDNA, from serial liquid biopsies to provide information on disease progression and drug resistance
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is pleased to announce that the world-class research team led by Prof. Evi Lianidou at the National and Kapodistrian University of Athens (Greece), has published results of a further study undertaken in non-small cell lung cancer (NSCLC) patients with an EGFR mutation being treated with the tyrosine kinase inhibitor (TKI), Osimertinib (AstraZeneca’s Tagrisso(R) ), which demonstrates the benefit of longitudinal analysis of epigenetic alterations in circulating tumour cells (CTCs), in addition to circulating tumour DNA (ctDNA), to assess possible drug resistance mechanisms in patients.
The aim of the study was to analyse increased DNA methylation in the promoters of six selected genes that result in loss of gene expression and are implicated in drug resistance in lung cancer. The analysis was performed using ctDNA and paired CTCs from a single blood sample. The study used the Parsortix(R) system to harvest CTCs in blood samples from 42 metastatic NSCLC patients before treatment with Osimertinib and again at disease progression.
After harvesting from the Parsortix system, captured CTCs were lysed and the genomic DNA extracted. Once DNA integrity had been evaluated, the DNA was amplified and expression levels assessed using real-time methylation specific PCR (MSP) assays for the targeted genes. CTC-derived DNA was analysed in 74 samples and DNA methylation assessed before treatment and at disease progression. For the first time, direct comparison of the CTC results with 70 paired results from 80 ctDNA samples has revealed significant differences in DNA methylation indicating that CTCs and ctDNA give complementary information and demonstrate a high level of heterogeneity between patients even at the DNA methylation level.
Moreover, the combined results from CTC and ctDNA methylation analysis indicated that methylation rates for all genes tested were significantly elevated at progression of disease after treatment with Osimertinib compared to before treatment , indicating that DNA methylation of these genes may be associated with resistance to Osimertinib during therapy. As a result, identifying the differences between DNA methylation in ctDNA and CTCs in longitudinal studies could help guide therapy decisions and provide an important enhancement to monitoring patient response in cancer drug trials.
In the United States, lung cancer is the second most common cause of cancer and the leading cause of cancer related mortality, responsible for 22% of all cancer related deaths. In 2021, The National Cancer Institute predicts that there will be a total of 236,000 new cases and 132,000 deaths - NSCLC accounts for 84% of all lung cancer cases. Whilst the overall 5-year survival rate for NSCLC is 25%, 60% of patients are diagnosed with metastatic (stage IV) disease for which the 5-year relative survival rate is just 5%.
However, lung tissue biopsy required for biomarker assessment is associated with significant risks. Due to adverse events following the procedure, a mean cost of US$14,600 per biopsy has been estimated. Liquid biopsy offers the potential for safe, cost-effective longitudinal monitoring of tumour evolution and disease progression to track mutations responsible for therapy resistance and identify biomarkers for targeted treatment selection.
Precision medicine has transformed cancer care in NSCLC. There are 34 FDA approved therapeutics for NSCLC, 24 of these are targeted therapies including PD-L1/PD-1 inhibitors which can induce durable and long lasting antitumour immunity. Patient response to PD-L1 or PD-1 inhibitors is variable ranging from 13%-50% but treatment costs c. US $170,000 per patient and has significant side effects. As such, there is a clear need for improved patient selection to identify responders given that non-responders risk the development of hyper-progressive disease and immune-related adverse events, and the wasted healthcare costs are significant.
There are over 2,400 clinical studies registered at clinicaltrials.gov involving PD-L1, all of which may benefit from a CTC based biomarker to assess PD-L1 status over time. ANGLE is currently validating a PD-L1 assay in its clinical laboratories which will be offered to biopharma customers for use in clinical trials.
Thu 13 Jan 2022 07:00
RNS Number : 2810Y
Angle PLC
13 January 2022
For immediate release
13 January 2022
ANGLE plc (“the Company”)
UPDATE ON LABORATORY ACCREDITATION AND OVARIAN CANCER STUDY
First submissions made in relation to accreditation of ANGLE clinical laboratories
Ovarian cancer study sample analysis slower than planned
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, provides an update on its plans for accreditation of its clinical laboratories and on its ovarian cancer study.
First submissions have been made in relation to CLIA and UKAS accreditation of the Company’s United States and UK clinical laboratories respectively. In the United States, these processes are in hand pending results of the ovarian cancer study evaluating the combined use of ANGLE’s Parsortix® and HyCEAD™ platforms as a simple blood test to detect the presence of ovarian cancer in women with an abnormal pelvic mass, which is nearing completion.
While good progress has been made in many areas of the ovarian cancer study, there have been some third-party supply chain difficulties attributed to COVID-19. A key supplier has been unable to deliver certain reagents as scheduled. Completion of the study sample analysis depends on these reagents and the situation is being closely managed. Consequently, headline results for the study are now expected in H1 2022.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The third-party supply chain issues were unexpected but are being closely managed and we look forward to reporting headline results from our ovarian cancer study once the sample analysis has been completed.
Separately, we remain on track to achieve the first ever FDA product clearance, the gold standard for medical devices globally, for a system to harvest cancer cells from patient blood for subsequent analysis, initially in metastatic breast cancer. Ongoing and constructive dialogue with FDA continues and a regulatory decision from FDA is awaited."
Mon, 17th Jan 2022 07:00
RNS Number : 5460Y
Angle PLC
17 January 2022
For immediate release
17 January 2022
BREAKTHROUGH STUDY DEMONSTRATES FOR THE FIRST TIME CONCORDANCE OF PARSORTIX LIQUID BIOPSY BLOOD TEST WITH INVASIVE TISSUE BIOPSY OF THE METASTATIC SITE
ANGLE Founder and Chief Executive, Andrew Newland, added:
“ANGLE is delighted to report on this breakthrough research published by Dr Julie Lang and her team, which clearly demonstrates the ability to use the Parsortix system with a simple blood test as an alternative to invasive tissue biopsy in metastatic breast cancer. The RNA-Seq technology used allows full RNA sequencing of the cancer providing information on the whole transcriptome. Analysis of CTCs using RNA-Seq was a key component of our FDA submission and we believe this form of analysis has the potential to bring great benefit to patients through access to information to guide treatment decisions as well as reducing the need for invasive procedures and associated costs.”
Study explores key unmet medical need for metastatic breast cancer as over 50% of patients fail to receive successful tissue biopsies of the metastatic site preventing access to essential information to guide their treatment
Potential for Parsortix liquid biopsy blood test as an alternative to invasive surgical tissue biopsy in metastatic breast cancer
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce the publication of breakthrough research undertaken by the world-class team at the University of Southern California Norris Cancer Center. The research demonstrates the potential of circulating tumour cells (CTCs) harvested from a simple blood draw using the Company’s Parsortix® system to be used as an alternative to invasive metastatic tissue biopsy for metastatic breast cancer (MBC) patients.
In the United States, guidelines published by the National Comprehensive Cancer Network (NCCN) recommend a tissue biopsy of a secondary cancer site in MBC because of the critical need for up-to-date information on cancer progression to guide treatment decisions. However, over 50% of all MBC patients do not have a successful metastatic tissue biopsy because they are either too ill for the invasive procedure, the cancer site is inaccessible and/or insufficient tissue is available. Hence, there is nothing to guide ongoing treatment decisions in these patients. Even in those patients who can undergo a metastatic tissue biopsy, there is rarely the option for a second such biopsy, yet the cancer continues to evolve, often to multiple sites. A simple, repeatable liquid biopsy alternative using the Parsortix system could resolve the issues with metastatic tissue biopsies and, as the study finds, provide real time information on the cancer evolution to guide treatment options.
The study was the first of its kind to directly compare molecular analysis of matched patient samples from invasive metastatic tissue biopsy with Parsortix-harvested cells from a blood sample. The demonstration of a high concordance between the RNA sequencing (RNA-Seq) results of the two sample types is critical in demonstrating the potential utility of the Parsortix system for use as a routine blood test for cancer patients, which could provide a view on the spread of the disease. It is particularly important as over 90% of patients who die of their cancer die of the metastatic spread of the disease rather than their primary cancer.
The pilot study, in 19 patients with MBC, investigated whether gene expression profiling of cancer-related cells, harvested from a blood sample with the Parsortix system, using RNA-Seq technology, could provide insight into targetable mutations with the hypothesis that a Parsortix system liquid biopsy could be utilised as a surrogate biomarker to replace tissue biopsy in the analysis of metastases. Gene expression analysis (RNA) was chosen in preference to gene sequencing (DNA), because of major concerns that not all DNA mutations are expressed and therefore clinically relevant information is missed. ANGLE’s Parsortix system was chosen for its efficient, unbiased marker-independent isolation method and the Parsortix system-harvested cells were characterised through RNA-Seq alongside matched metastatic tissue biopsy samples.
The authors reported a high degree of concordance between matched Parsortix system and metastatic tissue samples in clinically actionable genes, demonstrating how the Parsortix system could be utilised as a non-invasive, repeatable liquid biopsy to provide real time insight into MBC disease biology and inform targeted treatment selection. Furthermore, in three of four patients with progressive disease, the Parsortix system-enabled longitudinal analysis revealed a significant increase in the complexity and frequency of expressed mutations over time. These results indicate that the Parsortix system-enabled longitudinal monitoring could capture changes in mutational burden as the cancer evolves, including the development of resistance to anti-cancer therapies which could help guide clinical decision-making and treatment selection.
Breast cancer is the leading cause of cancer worldwide with 2.2 million new cases estimated in 2020. MBC is responsible for virtually all breast cancer deaths and for the 6% of patients diagnosed with metastatic disease or patients whose disease has progressed to stage IV, 5-year relative survival is only 29%.
The research has been published as a peer-reviewed publication in the journal Annals of Surgical Oncology and can be accessed at Publications/Posters - ANGLE PLC.
Dr Julie Lang, Chief of Breast Surgery and Co-Director of Comprehensive Breast Cancer Program at Cleveland Clinic Cancer Center, formerly Director, USC Breast Cancer Program, Associate Professor of Surgery, Norris Comprehensive Cancer Center, University of Southern California commented:
“Gene expression sequencing of Parsortix system-enriched CTCs could lead to minimally invasive, real time diagnostic strategies for precision therapeutic decision-making for MBC patients. Our Parsortix-based liquid biopsy approach could serve as a surrogate tissue biopsy to evaluate potentially clinically actionable drug target gene expression and mutations, allowing longitudinal assessment of the evolution of a patient’s cancer for personalized care.”
2 Likes
Another RNS today
I cant confess to understanding the science
ANGLE plc (“the Company”)
PEER-REVIEWED PUBLICATION HIGHLIGHTS POTENTIAL FOR PARSORTIX SYSTEM IN IMMUNOTHERAPY TREATMENT SELECTION
Parsortix isolation of CTCs highlights relationship between PD-L1 expression and epithelial to mesenchymal transition (EMT)
CTCs in the process of epithelial mesenchymal transition (EMTing CTCs) found to be most closely associated with PD-L1 expression
ANGLE Founder and Chief Executive, Andrew Newland, commented:
“We are pleased to report on this promising pilot data showcasing the utility of the Parsortix system for the unbiased isolation of multiple subsets of CTCs in ovarian cancer patients. Whilst ctDNA is increasingly used for the stratification of cancer patients, it is unable to provide insight into PD-L1 status. In contrast, CTCs can provide PD-L1 status. ANGLE is currently in the process of validating a PD-L1 assay in its clinical laboratories as a key part of its pharma services offering for clinical trials.”
AGL today received FDA approval
this is Big news - they are the first to obtain such a consent and reckon they have first mover advantage on this massive market *estimated to be $100bn in the US alone
its bee a 6 year process
Well Done AGL!
1 Like
Price has drifted since FDA news
Placing done last week at 80p per share but the price then fell below that level
RNS this pm that Baillie Gifford & Co has declared a holding of 5.73% (no previous holding disclosed)
hope this marks the low point and up from here
2 Likes
News yesterday on a liquid biopsy test for some types of ovarian cancer
Researchers reported “unprecedented sensitivity and specificity”
Angle has refrained from releasing further data, as it believes that the diagnostic algorithms (combining Parsortix findings, RNA markers and patient data) that were developed during the trials could be patented.
credit to:
Edison’s Flash Note
https://www.edisongroup.com/publication/milestone-in-ovarian-cancer-application/19168/
1 Like
2 RNS today
1 for interims
the other is
ANGLE REPORTS POSITIVE HEADLINE RESULTS FROM OVARIAN CANCER CLINICAL VERIFICATION STUDY
ANGLE Founder and Chief Executive, Andrew Newland, commented:
“Demonstration of clinical utility of the Parsortix system is a key strategic goal for ANGLE, so the excellent results from this study are validation of what can be achieved in a demanding clinical setting. Further, these results demonstrate the capability to undertake a complex molecular analysis of the Parsortix harvest in a real world setting. This important capability has potentially numerous, widespread alternative uses, reinforcing our belief that a Parsortix harvest of circulating tumour cells from a liquid biopsy offers the “best sample” for clinicians seeking actionable information to guide patient cancer treatment.”
https://polaris.brighterir.com/public/angle_plc/news/rns/story/rg99p3x